Disentangling MRI-derived blood–brain barrier leakage into vascular permeability and surface area

Damon Verstappen, Joost JA de Jong, Paulien HM Voorter, Maud van Dinther, Robert J van Oostenbrugge, Julie Staals, Jacobus FA Jansen, Walter H Backes · 2026

Read Disentangling MRI-derived blood–brain barrier leakage into vascular permeability and surface area by Damon Verstappen, Joost JA de Jong, Paulien HM Voorter, Maud van Dinther, Robert J van Oostenbrugge, Julie Staals, Jacobus FA Jansen, Walter H Backes (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13586075.txt.

Introduction

Damon Verstappen and co-authors split a common brain scan measure of blood-brain barrier leakage into two parts, in a 2026 study. The barrier keeps blood contents out of brain tissue. In small vessel disease, leaks are subtle and spread out. Standard scan measures mix true wall leakiness with the size of the vessel surface.

The team scanned patients with small vessel disease and healthy older controls. One scan type measured the leakage rate, and another estimated vessel surface area. Dividing one by the other gave the wall permeability itself. Leakage differed between diseased and normal-looking white matter. Separating the parts may sharpen diagnosis and drug trials. It clarifies what a leak really means in each patient.

Catalog record

CREATORDamon Verstappen, Joost JA de Jong, Paulien HM Voorter, Maud van Dinther, Robert J van Oostenbrugge, Julie Staals, Jacobus FA Jansen, Walter H Backes
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13586075

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Disentangling MRI-derived blood–brain barrier leakage into vascular permeability and surface area Authors: Damon Verstappen, Joost JA de Jong, Paulien HM Voorter, Maud van Dinther, Robert J van Oostenbrugge, Julie Staals, Jacobus FA Jansen, Walter H Backes Published: 2026 ABSTRACT AbstractIn neurovascular and neurodegenerative diseases, blood–brain barrier (BBB) disruption can be subtle and diffuse, and MRI-derived measures are confounded by microvascular architecture. Therefore, we aimed to disentangle the MRI-derived blood–brain barrier leakage rate (Ki) into intrinsic vascular permeability (P) and surface area (S). In this cross-sectional study, 45 patients with cSVD and 26 elderly controls underwent dynamic contrast-enhanced (DCE) MRI to determine Ki and vessel architecture imaging (VAI) to estimate S. These measures were used to calculate P. Compared to normal-appearing white matter (NAWM), Ki was higher in WMH (β = 0.297, p < 0.001) and deep gray matter (DGM; β = 0.210, p = 0.007). P was higher in WMH (β = 0.410, p < 0.001) and similar between NAWM and DGM. S was smaller in WMH (β = −0.467, p < 0.001) and larger in DGM (β = 0.540, p < 0.001). Ki (β = 0.289, p = 0.007) and P (β = 0.249, p = 0.021) were only higher in patients than controls in concentric shells surrounding WMH. S was smaller in WMH of patients than controls (β = −0.085, p = 0.049). With age, Ki (β = 0.260, p = 0.008) and P increased (β = 0.273, p < 0.001), while S decreased (β = −0.079, p = 0.025). Disentangling P and S from the BBB leakage rate provides two biologically more specific and interpretable measures, which have counteracting effects on the BBB leakage in aging and disease.Keywords: Blood–brain barrier, cerebral small vessel disease, dynamic contrast-enhanced MRI, permeability, surface area Introduction Contrast-enhancement in brain tissue is generally considered as evidence of blood–brain barrier (BBB) breakdown. 1 The degree of BBB disruption is commonly determined by dynamic contrast-enhanced (DCE) MRI and pharmacokinetic modeling, yielding the leakage rate (Ki) as a key quantitative BBB integrity (bio)marker. 2 However, for neurovascular and neurodegenerative brain diseases and also aging, this leakage may not only be subtle and hard to determine, 3 but also confounded by the underlying microvascular density. 2 In particular, microvascular rarefaction as co-morbid brain pathology or aging phenomenon may obscure BBB permeability increases due to counterbalancing effects of increased intrinsic permeability and decreased microvascular surface area on Ki (Figure 1).3,4 In line with this, higher Ki in gray matter (GM) than in white matter (WM) is commonly ascribed to higher microvascular density in GM.5,6 Consequently, regional Ki differences should not be unambiguously attributed to BBB breakdown, but also changes in microvascular density. The counteracting effect of vascular surface area (S) and intrinsic vascular permeability (P) on the blood–brain barrier leakage rate (Ki). Conceptually, a similar leakage rate can be obtained by the combination of a higher S and lower P as a lower S and higher P. Currently, no explicit measurement techniques are available to measure either the intrinsic permeability or the surface area of cerebral microvessels. 2 However, with vessel architecture imaging (VAI), it has recently become possible to measure the microvascular density and average vessel radius, which has been histologically validated in a number of studies.7–9 VAI is an advanced MRI perfusion technique, which exploits the differential sensitivity of spin-echo (SE) and gradient-echo (GE) sequences to various vessel sizes. 7 This work uses knowledge of vessel sizes in combination with cerebral blood volume (CBV) to estimate the microvascular surface area (S) and to derive the intrinsic vascular permeability (P). By separating vascular permeability from surface area, this study provides novel images of microvascular properties in patients with cerebral small vessel disease (cSVD) and elderly, for which a substantial range in microvascular pathology can be expected. We set out to establish the variation of P and S across major brain tissue types and evaluate the association of cSVD and age with these microvascular measures. In particular, we evaluated the heterogeneity of intrinsic permeability around characteristic white matter hyperintensities (WMH) presumed to be caused by variations in the underlying small vessel damage. 10 Methods Study population Data were acquired from the miCRovascular rarefaction in vascUlar Cognitive Impairment and heArt faiLure (CRUCIAL-VCI) study (trial registration: ISRCTN22301128). 11 In this prospective, cross-sectional study, patients with cSVD, who presented with vascular cognitive impairment (VCI) or a lacunar infarction were recruited from the memory or stroke clinic of the Maastricht University Medical Center+, The Netherlands. Recruitment took place between December 2020 and October 2024. The definition of VCI due to cSVD was: subjective complaints of cognitive functioning, objective cognitive impairment in at least one cognitive domain in neuropsychological assessment or a Montreal Cognitive Assessment (MoCA) score <26, and imaging evidence of cSVD 12 (extensive leukoaraiosis on CT, or moderate to severe WMH on MRI (Fazekas score ⩾2), or mild WMH (Fazekas score = 1) in combination with lacunes or microbleeds). 13 Inclusion criteria for the lacunar stroke due to cSVD group were: a classical lacunar stroke syndrome with a compatible lesion on CT or MRI, and additional imaging evidence of cSVD (mild to severe WMH and/or microbleeds). Patients were scanned >3 months after the stroke to minimize acute post-stroke effects. Finally, we included a group of age-and-sex-matched controls from the neurology outpatient clinic where they presented with minor compression mononeuropathy or lumboischialgia. These controls did not undergo MRI prior to inclusion. Therefore, covert signs of cSVD were not ruled out, but the controls had no overt cognitive impairment or overt cerebrovascular disease. Exclusion criteria included a Clinical Dementia Rating score >1, 14 other neurological or psychiatric conditions affecting the brain and general contraindications for MRI or to tolerate gadolinium-based contrast agents. This study was approved by the Medical Ethics committee of the Maastricht University Medical Centre (approval number: NL72696.068.20). All participants provided written informed consent in accordance with the Declaration of Helsinki. MRI acquisition All images were acquired using a 3 T MRI system (Philips Ingenia CX; Philips Healthcare, Best, The Netherlands) equipped with a 32-element head coil. The imaging protocol included two separate dynamic contrast-enhanced pulse sequences, one for DCE–MRI and the other for VAI. The DCE–MRI protocol consisted of one 1-mm resolution pre-contrast T1 map and two post-contrast T1 maps spaced >20 min apart, to improve sensitivity to subtle leakage. 15 These maps were acquired using a double inversion time (TI) gradient echo (GE) sequence (TR = 8.3 ms, TE = 3.8 ms, TI1 = 650 ms, TI2 = 2100 ms, FA = 6°, matrix size = 240 × 240, voxel size = 1 mm3). Hemodynamics were determined using a fast saturation recovery 3D DCE scan (TR = 5.3 ms, TE = 1.6 ms, saturation prepulse time delay (TD) = 120 ms, FA = 30°, matrix size = 128 × 128, voxel size = 2 × 2 × 6 mm, number of dynamics = 70, dynamic scan interval = 1.46 s) during contrast agent administration. 10 For VAI, a rapid transverse single-shot combined GE SE echo-planar-imaging (EPI) sequence (Gyrotools LLC, Zurich, Switzerland; TR = 1634 ms, TEGE = 25 ms, TESE = 78 ms, FA = 90°, matrix size = 76 × 61, voxel size = 3.0 × 3.3 ×

Read the complete text